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Porcine reproductive and respiratory syndrome virus (PRRSV) is responsible for significant economic losses in the
porcine industry. Currently available commercial vaccines do not allow optimal and safe protection. In this study,
replicating but nondisseminating adenovectors (rAdV) were used for the first time in pigs for vaccinal purposes.
They were expressing the PRRSV matrix M protein in fusion with either the envelope GP5 wild-type protein (M-GP5)
which carries the major neutralizing antibody (NAb)-inducing epitope or a mutant form of GP5 (M-GP5m)
developed to theoretically increase the NAb immune response. Three groups of fourteen piglets were immunized
both intramuscularly and intranasally at 3-week intervals with rAdV expressing the green fluorescent protein (GFP,
used as a negative control), M-GP5 or M-GP5m. Two additional groups of pigs were primed with M-GP5m
-expressing rAdV followed by a boost with bacterially-expressed recombinant wild-type GP5 or were immunized
twice with a PRRSV inactivated commercial vaccine. The results show that the rAdV expressing the fusion proteins
of interest induced systemic and mucosal PRRSV GP5-specific antibody response as determined in an ELISA.
Moreover the prime with M-GP5m-expressing rAdV and boost with recombinant GP5 showed the highest antibody
response against GP5. Following PRRSV experimental challenge, pigs immunized twice with rAdV expressing either
M-GP5 or M-GP5m developed partial protection as shown by a decrease in viremia overtime. The lowest viremia
levels and/or percentages of macroscopic lung lesions were obtained in pigs immunized twice with either the rAdV
expressing M-GP5m or the PRRSV inactivated commercial vaccine.Introduction
Porcine reproductive and respiratory syndrome (PRRS)
emerged in the late 1980s in North America [1] and
then later in Europe [2]. Since then, the disease has
spread worldwide and become one of the most serious
infections in the swine industry with an estimated loss of
$ 664 million per year in the USA in 2011 [3]. PRRS is
characterized by severe respiratory clinical signs associ-
ated with pneumonia in pigs of all ages and reproductive
disorders in sows associated with late term abortion or* Correspondence: archambault.denis@uqam.ca
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reproduction in any medium, provided the orpremature farrowing and an increased number of still-
born piglets [4].
The causative agent of PRRS, the porcine reproductive
and respiratory syndrome virus (PRRSV), belongs to the
Arteviridae family which together with the Coronaviridae
and Roniviridae families constitute the Nidovirales order
[5]. The PRRSV genome is a positive, single-stranded, 5’-
capped and 3’-polyadenylated mRNA molecule with a
length of approximately 15 000 nucleotides (nt). It con-
tains, in the direction 5’-3’, two large open reading frames
(ORF), ORF 1a and 1b, which encode the viral replicase
and represent approximately three-quarters of the gen-
ome, and seven smaller ORF designated 2a, 2b and 3 to 7
which express structural proteins termed GP2a, GP2b,
GP3, GP4, GP5, M and N, respectively [6]. An additionalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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native ORF from the subgenomic viral mRNA encoding
GP5 [7].
GP5 is a glycosylated envelope protein of approxi-
mately 25 kDa, carrying the major neutralizing epitope.
An immunodominant region localized in the ectodomain
of GP5 contains a so-called decoy epitope (amino acids
(aa): 27–30 A/(V)LVN) [8]. Soon after infection, this epi-
tope induces a strong non-neutralizing antibody (Ab) re-
sponse and a delay in the production of neutralizing Ab
(NAb) which generally appears after three weeks post in-
fection [8,9]. However, the decoy epitope is not the only
way for PRRSV to escape the host Ab response. GP5 con-
tains several N-glycosylation sites located at or near the
neutralizing epitope (aa 37 to 45: SHLQLIYNL) [10]. Abro-
gation of the N34 and N51 glycosylation sites within an in-
fectious clone of PRRSV induces in the pig a faster and
more efficient NAb response than the wild-type clone [11].
In contrast, it was reported that wild-type PRRSV strain in-
duces a more rapidly and more strongly NAb response in
infected pigs than natural mutant isolates carrying a
disrupted N44 glycosylation site [12]. The GP5 protein is
associated within the virion to the membrane protein M
via disulfide bonds [13]. M is a non-glycosylated protein of
approximately 19 kDa associated with a strong cellular im-
mune response [14]. The use of GP5 either co-expressed
or in fusion with M using various genetic vectors generates
a better NAb response against GP5 than the use of GP5
alone [15-17].
Although there are several vaccines commercially
available, these may have several pitfalls. Attenuated live
vaccines present a risk of reversion to virulence [18]
whereas inactivated vaccines may not confer optimal
protection [19,20]. Because of this, several vaccine strat-
egies have been developed against PRRSV. Most of these
strategies rely on the use of DNA-based vaccines [21-26],
transgenic plants [27,28], bacterial vectors [29-31], or viral
vectors. Among the viral vectors used are non-replicative
human [17,32-39] and canine adenoviruses [40], transmis-
sible gastroenteritis virus [41], the modified strain of
vaccinia virus [16], pseudorabies virus [15,42] and fowlpox
virus [43]. Approximately half of these immunization
studies were conducted in pigs that were then exposed to
an experimental challenge, but only a few compared their
efficacy with commercially-available vaccines [15,23,42].
In all these strategies a partial protection of immunized
pigs was demonstrated [41].
Replicating but nondisseminating human adenovi-
ruses serotype 5 (rAdV) have been developed. These
adenovectors are devoid of functional protease (PS)
gene, preventing the maturation process of capsid pro-
teins and assembly of viral particles [44]. For this reason
these vectors are considered safe because of their inabil-
ity to spread among the population [45]. In addition,these vectors are functional in the E1A gene, allowing
replication of the viral genome, and, thereof, expression
of the proteins of interest to high levels within the inoc-
ulated host [45]. Finally, these adenovectors are of the
human type rendering them very attractive for use in
the pig which is fully permissive to the vector and does
not have vector-specific pre-existing immunity [46].
In this study, the rAdV described above were used for
the first time in pigs. rAdV were generated to express
the PRRSV M protein in fusion with GP5 wild-type (M-
GP5) or with a mutant form of GP5 (M-GP5m) that the-
oretically increases NAb response. Pigs were immunized
with rAdV expressing GFP (negative control), M-GP5 or
M-GP5m. Two additional groups were immunized once
with rAdV expressing M-GP5m and boosted with re-
combinant bacterial GP5 (M-GP5m/rGP5 group) or twice
with a PRRSV commercial inactivated vaccine (inactivated
vaccine group) respectively. The results show that all im-
munized animals generated a GP5-specific Ab response.
Pigs of the M-GP5m/rGP5 group developed the highest
Ab response. Pigs that received the rAdV expressing M-
GP5m or the inactivated vaccine twice showed the lowest
viremia levels and/or percentages of macrocospic lung le-
sions after an experimental challenge with PRRSV.
Material and methods
Viruses, cells and synthetic genes
PRRSV IAF-Klop [33] and FMV09-1155278 (C.A. Gagnon,
unpublished) strains were propagated in Dulbecco’s modi-
fied Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA,
USA) supplemented with 8% fetal bovine serum (FBS; PAA
Laboratories, Inc., Etobicoke, Ontario, USA) at 37°C in a
humidified atmosphere of 5% CO2 [35] and titrated in
MARC-145 cells using the Kärber method [47].
rAdV were propagated and titrated in the 293-PS
-CymR cell line which is a cell clone derived from the
HEK 293 cell line expressing the protease (PS) gene [44].
Cells were grown in DMEM supplemented with 8% FBS
and 50 μg/mL cumate (Sigma-Aldrich, St. Louis, MO,
USA) at 37°C in a 5% CO2 humidified atmosphere as de-
scribed [48].
A549 cells were propagated in DMEM supplemented
with 8% of FBS and maintained at 37°C in a humidified
atmosphere of 5% CO2. Unlike the HEK 293 cells, these
do not express proteins encoded by the adenovirus E1
gene and were used to confirm protein expression from
the rAdV [44].
The codons most frequently used in Sus scrofa cells
and demonstrated for their ability to increase the im-
mune response in swine [35] were used to generate the
GP5 (ORF5)- and M (ORF6)-encoding genes (synthe-
sized through GeneArt services; Invitrogen) on the basis
of the PRRSV IAF-Klop genome sequence [Genbank ac-
cession number: U64928].
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with the M sequence
Three mutations to increase the Ab and T cell immune re-
sponses specific to GP5 [22,25] were introduced by PCR in
the GP5-encoding gene. The first mutation consisted in
the replacement of the GCCCTGGTGAAC nucleotide (nt)
sequence (aa 27–30: ALVN) by the TCTGGGTCTGGC nt
sequence (aa 27–30: SGSG) to abolish the decoy ALVN
epitope [8]. The second mutation introduced the 39 nt
PADRE sequence (AKFVAAWTLKAAA) between residues
32 and 33 such that this sequence was localized between
the abrogated decoy sequence and neutralizing epitope
[25]. The third mutation replaced the AAC triplet (N) by
the GCC triplet (A) to abolish the N51 glycosylation site
[22]. The resultant protein produced from the mutated en-
coding gene was designated hereafter GP5m. GP5 wild-
type- or GP5m-encoding sequences were fused by PCR to
the 3’ terminal of the M gene with the insertion of the
GTTACCACC (GTT) linker sequence between the M and
GP5-encoding nt sequences [17]. The sequences were vali-
dated by DNA sequencing through the McGill University
Sequencing Services (Montréal, QC, Canada).
Construction of recombinant adenoviruses (rAdV)
The M-GP5- and M-GP5m-encoding sequences were
inserted into the BglII site of the adenovirus transfer
vector pAdenoVator-CMV5(CuO)-IRES-E1A [45]. The
recombinant plasmids were rescued into the genome of
the pAdeasyΔPS by homologous recombination in E. coli
BJ5183 cells (MP Biomedicals, Irvine, CA, USA) through
electroporation (2.5 kV, 200 Ohms and 25 μF). The re-
combinant rAdV genome was confirmed by PCR and re-
striction enzyme analysis. To produce the rAdV, plasmids
were linearized by PacI digestion and 293-PS-CymR cells
at 60% confluency were transfected with 2 μg of each plas-
mid (one well per plasmid of a 6-well tissue culture plate)
using PolyFect transfection reagent (Qiagen, Valencia, CA,
USA). The transfected cells were overlaid 24 h later with
agarose (Invitrogen) (0.45% in DMEM supplemented with
5% FBS) and monitored daily until the appearance of viral
plaques. After the confirmation of transgene expression
from amplified viral clones, rAdV were produced at a
large scale and purified by double cesium chloride gradi-
ent [45]. The infectious dose of rAdV was determined in
293-PS-CymR infected cells using the Kärber method and
titers were expressed in tissue culture infectious dose 50
per mL (TCID50/mL).
Western blot assay
A549 cells were seeded in 6-well tissue culture plates
and infected with rAdV with a multiplicity of infection
(MOI) of one. At 24 h post-infection, cells were lysed
with lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl,
1% triton X-100 and EDTA-free protease-inhibitorcocktail (Roche, Indianapolis, IN, USA)) and total cell
protein concentration was quantified with the DC pro-
tein assay kit (Bio-Rad, Mississauga, ON, CA, USA). For
each sample, 20 μg of total cell extract was electrophor-
etically separated onto 12% SDS-PAGE and transferred
to nitrocellulose membranes (Bio-Rad). The membranes
were blocked in phosphate buffered saline (PBS) solu-
tion, pH 7.3, containing 0.05% Tween-20 (PBS-T) in the
presence of 5% nonfat dry milk powder for 1 h at room
temperature. The membranes were incubated overnight
at 4°C with convalescent homologous PRRSV-specific
pig antiserum obtained from a previous study [49] used
at a 1/5000 dilution, or mouse monoclonal Abs specific
to either adenovirus E1A (1/5000) (Millipore, Bedford,
MA, USA), GFP (1/5000) (Roche) or GAPDH (1/10 000)
(Sigma-Aldrich, St. Louis, MO, USA) proteins. Following
incubation, membranes were washed three times with
PBS-T and then incubated for 1 h at room temperature
with anti-pig horseradish peroxidase (HRP)-conjugated
IgG (Sigma-Aldrich) or anti-mouse-HRP-conjugated IgG
(Bethyl, Montgomery, TX, USA). The signal was detected
by enhanced chemiluminescence (ECL) (Perkin Elmer,
Boston, MA, USA). The membranes were then exposed to
Kodak Biomax Light-1 films.
Recombinant GP5 production
Plasmid pGEX4T1 (Pharmacia Biotech, Piscataway, NJ,
USA) encoding wild-type GP5 of the PRRSV IAF-Klop
strain was obtained from a previous study [50]. Recom-
binant GP5 in fusion with Glutathione S-transferase
(GST), designated hereafter rGP5, was produced in BL21
(DE3)pLysS competent E. coli cells (Promega, Madison,
WI, USA) upon induction at OD(600 nm) of 1.2 with 0.1
mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4
h at 37°C. Bacterial cells were lysed by sonication in buffer
(PBS, 0.5% Tween-20, 0.5% triton X-100, 0.5% NP40) and
the whole bacteria protein extract was separated through
12% SDS-PAGE. The band corresponding to the rGP5
expected molecular weight was excised from the gel and
electroeluted. The purified protein was dialyzed against
PBS. The protein concentration was quantified with the
DC protein assay kit as described above. The identity of
the eluted protein was confirmed by Western blot using
convalescent PRRSV-specific pig antiserum as above. The
protein stock was then stored at −80°C for further use.
Immunization of piglets and experimental challenge
Animal protocols were approved by the University’s and
the Dairy and Swine Research and Development Centre’s
(DSRDC) Animal Protection Institutional Committees
according to the regulations of the Canadian Council for
Animal Care. Seventy, three-week-old, Yorkshire-Landrace
x Duroc pigs from the herd located at the DSRDC, Agri-
culture and Agri-Food Canada (Sherbrooke, QC, Canada)
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into five groups of 14 pigs according to a randomized
complete block design. The pigs were housed in the nur-
sery rooms of the DSRDC swine complex. For each group,
six pigs were kept separately for subsequent experimental
challenge. Pigs were fed ad libitum with commercial non-
medicated feed and had access to water. The swine herd
was seronegative for PRRSV, transmissible gastroenteritis
virus, Mycoplasma hyopneumoniae and Actinobacillus
pleuropneumoniae prior to the experiment.
Pigs of three groups were immunized by both the
intramuscular (IM) and intranasal (IN) routes at days 0
and 21 with 108 TCID50 of rAdV expressing GFP (nega-
tive control), M-GP5 or M-GP5m. Pigs of group four
were primed at day 0 IM and IN with 108 TCID50 of
rAdV expressing M-GP5m, and boosted at day 21 IM
with 250 μg of rGP5 supplemented with 500 μg of
QuilA (Brenntag Biosector, Frederikssund, Denmark),
and mixed in equal volume with Freund’s incomplete
adjuvant (Sigma-Aldrich). This group was designated
M-GP5m/rGP5 hereafter. Pigs of group five were inocu-
lated at days 0 and 21 IM with 2 mL of the commercial
Ingelvac PRRSV MLV vaccine (Boehringer Ingelheim, St
Joseph, MO, USA) inactivated 1 h at 56°C prior to the
inoculation (designated hereafter as the inactivated vac-
cine). The inactivation process was conducted to avoid
unwanted propagation of live PRRSV in the PRRSV-free
swine herd of the research center. For IN immunization,
pigs were sedated with stresnil (6–8 mg/kg of weight)
given by the IM route. Blood samples were collected at
0, 21, 28, 35 and 49 days post-immunization (dpi). At 49
dpi, 8 pigs of each group were sedated and anesthetized
(10 mg/kg of ketamine and 5 mg/kg xylazine) prior to
being euthanized by exsanguination. The animal lungs
were collected to perform bronchoalveolar lavage with
30 mL of PBS, pH 7.3.
The remaining pigs (n = 6) of each group were trans-
ferred at 42 dpi to the Faculty of Veterinary Medicine of
the University of Montréal for experimental challenge.
After an adaptation time of 7 days, the pigs were chal-
lenged (e.g. at 49 dpi) IN with 2 × 105 TCID50 of the
PRRSV FMV09-1155278 strain. The FMV09-1155278
strain was selected for experimental challenge on the
basis of preliminary experiments in two pigs showing
viremia from day 3 following infection with the virus.
Animals were monitored daily for the presence of clin-
ical signs of cough, dyspnea, diarrhea and inappetence.
Blood samples were collected and rectal temperature
was monitored at 0, 3, 5, 7, 10, 14 and 21 days post-
challenge (dpc). Animals were weighed at days 0, 7, 14
and 21 dpc to determine the average daily body weight
gain. At 21 dpc, pigs were euthanized to perform bron-
choalveolar lavage with 30 mL of PBS as described above
and for pathological examination. Determination of thepercentage of macroscopic lung lesions, based on the
consolidation of lung tissues, was determined according
to a scoring system described elsewhere [51].Antibody response to PRRSV
Indirect ELISA
The presence of serum or bronchoalveolar lavage fluid
(BALF) GP5-specific Abs was evaluated by an indirect
ELISA using Immulon 2HB 96-well microtiter plates
(Thermo Labsystems, Franklin, MA, USA). The plates
were coated with 0.1 μg of rGP5 per well diluted in 0.05
M sodium carbonate buffered solution (pH 9.6) to a final
volume of 100 μL. Following an overnight incubation at
4°C, the plates were washed 4 times with PBS-T and
then saturated with 150 μL of PBS-T containing 1% bo-
vine serum albumin (BSA) overnight at 4°C. One hun-
dred μL of pig serum (used at a 1/200 dilution) or BALF
diluted two-fold in PBS-T with 1% BSA were added into
wells (in duplicate) and incubated for 2 h at 37°C. Plates
were washed as described above and anti-pig HRP-
conjugated IgG (used at a 1/10 000 dilution) or anti-pig
HRP-conjugated IgA (used at a 1/25 000 dilution) (AbD
Serotec, Raleigh, NC, USA) in PBS-T with 1% BSA were
added for 1 h at 37°C. Plates were washed and the HRP sig-
nal was detected by adding 100 μL of tetramethylbenzidine
(TMB, Sigma-Aldrich) per well. After an incubation of 20
min at room temperature, the reaction was stopped by
adding 50 μL 1M H2SO4 to each well. Optical density
(OD) was determined at 450 nm (using Tecan Infinite
M1000 reader, Tecan Group Ltd, Männedorf, Switzerland).
For each serum sample, the average OD was corrected by
subtracting the OD of the uncoated well from the OD
obtained with the antigen-coated well.ELISA IDEXX
The IDEXX PRRS X3 HerdChek ELISA (IDEXX Labora-
tories, Westbrook, ME, USA) was used for detection of
PRRSV-specific Abs in serum of animals. Serum samples
with a calculated S/P ratio greater than 0.4 were consid-
ered positive as recommended by the manufacturer.Serum neutralization assay
Serum or BALF samples were heat inactivated at 56°C for
30 min. Serial two-fold dilutions (starting at 1/2) of each
sample were done in DMEM, and the neutralization test
was performed by a viral cytopathic effect inhibition
method using the IAF-Klop or FMV09-1155278 strain,
105 cells/well of MARC-145 cells plated the day before the
assay and four wells per specimen dilution [52]. The NAb
titer was calculated at 96 h post cell infection and
expressed as the reciprocal of the highest sample dilution
neutralizing 100 TCID50 of the virus.
Roques et al. Veterinary Research 2013, 44:17 Page 5 of 13
http://www.veterinaryresearch.org/content/44/1/17Cellular immune response to PRRSV
Swine peripheral blood mononuclear cells (PBMC) from
pigs to be challenged afterwards with PRRSV were iso-
lated at 28, 35 and 49 dpi by density gradient centrifuga-
tion using Ficoll-Paque Plus (specific density of 1.077 g/
mL; GE Healthcare, Piscataway, NJ, USA). PBMC were
suspended in Roswell Park Memorial Institute 1640
medium (RPMI; Invitrogen) supplemented with penicil-
lin (100 U/mL)/streptomycin (100 μg/mL) (Invitrogen),
10% FBS, 0.05 mM β-mercaptoethanol (Fisher Scientific,
Nepean, Ontario, USA) and 10 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES, Invitrogen).
PBMC were seeded at a concentration of 4 × 105 cells
per well in 96-well plates. Quadruplicate wells were ex-
posed to 25 μL of either 200 TCID50 of heat-inactivated
PRRSV IAF-Klop strain, cell culture medium (control
cell cultures), or 1 μg/mL of Concanavalin A (Con A;
Sigma-Aldrich) used as a positive control for lymphocyte
functional activity. All cell cultures were incubated for 3
days at 37°C, and pulsed with 0.5 μCi of tritiated thymi-
dine (specific activity, 6.7 Ci/mmol, Perkin Elmer) 18 h
before harvesting cells onto a Wallac silica membrane
(Perkin Elmer). The bound radioactivity was measured
with Wallac Microbeta 1450 Trilux liquid scintillation
counter (Perkin Elmer). The cell blastogenic responses
were expressed by calculating the stimulation index (SI)
which represents the ratio of the mean counts per minute
(CPM) incorporated by the virus or mitogen-stimulated
containing cell cultures to the mean CPM incorporated by
the control cell cultures.E1A (40/42 kDa)
GAPDH (37 kDa)
M-GP5m (42.6 kDa)
1 2 3 4
M-GP5 (41.4 kDa)
GFP (27 kDa)RNA extraction and PRRSV real-time PCR
The QIAamp Viral RNA kit (Qiagen) was used to isolate
viral RNA from the serum samples at 0, 5, 7 and 10 dpc
as described in the manufacturer’s instructions. A com-
mercial PRRSV real-time PCR diagnostic kit (NextGen,
Tetracore Inc., Gaithersburg, MD, USA) was used for
PRRSV quantification as recommended by the manufac-
turer. The quantification of PRRSV was determined by
comparing the sample results with a standard curve
based on the amount of serially diluted IAF-Klop strain
produced in MARC-145 cells and titrated as TCID50/mL
of viral particles in the MARC-145-infected cell culture
supernatant [53]. The PRRSV qRT-PCR results were
expressed in TCID50/mL of serum. Figure 1 Expression of recombinant adenoviruses (rAdV)
in vitro. Western blot analysis of A549 cell lysates from mock
infected (lane 1) or infected with rAdV (MOI of 1) expressing GFP
(lane 2), M-GP5 (lane 3) and M-GP5m (lane 4). Immunoblot was
performed using GFP-specific mouse monoclonal antibody or a
convalescent PRRSV-specific pig antiserum as primary antibody and
an anti-mouse or anti-pig IgG-HRP as secondary antibody.
Replication capability of rAdV was confirmed by E1A expression
(lanes 2–4). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
immunostaining was used as a loading control.Statistical analyses
Data were analyzed with a Proc MIX procedure of SAS
(SAS Institute, Inc., Cary,NC, USA). Analysis of differ-
ences in Ab responses to GP5 in sera before and after
challenge was performed with a Kruskal-Wallis test with
Bonferroni adjustment. The other data were analyzed by
ANOVA with Tukey adjustment.Results
Expression of recombinant adenoviruses (rAdV)
Expression of proteins was detected by Western blot 24
h after infection of A549 cells with rAdV expressing
GFP, M-GP5 or M-GP5m. As shown in Figure 1, GFP as
well as M-GP5 and M-GP5m fusion proteins were
expressed at the expected 27, 41.4 and 42.6 kDa mo-
lecular weights, respectively (lanes 2 to 4). E1A gene
expression was confirmed in rAdV-infected cells, indi-
cating the capability of rAdV to replicate in non trans-
complementing cells.
Antibody (Ab) response in immunized pigs
As shown in Figure 2A, serum GP5-specific Abs were
detected from 28 dpi in pigs immunized twice with M-
GP5m-expressing rAdV (M-GP5m group), and to a
much higher level in pigs immunized with either rAdV
expressing M-GP5m followed by a boost with rGP5 (M-
GP5m/rGP5 group) or twice with the inactivated vac-
cine. Significantly higher Ab response was observed in
the M-GP5m/rGP5 group of pigs at 35 and 49 dpi when
compared to the other groups of immunized pigs (P <
0.005). The M-GP5m group generated a better Ab re-
sponse than that of the M-GP5 group at 28 (P < 0.01)
and 35 dpi (P < 0.005). The M-GP5 group indeed showed
the weakest Ab response among all groups of immunized
pigs at any time point. There was no difference between
the M-GP5m and inactivated vaccine groups at 28 and 35
dpi. In contrast, the Ab response observed in the
Figure 2 Antibody responses in pigs vaccinated with the recombinant adenoviruses. (A) IgG specific to GP5 were detected in serum
samples of pigs (n = 14 per group) at various time points by indirect ELISA. Bronchoalveolar lavage fluid (BALF) of pigs were collected at 49 days
post primary immunization and IgG (B) or IgAs (C) specific to GP5 were determined by indirect ELISA (n = 8 per group). Data are expressed as the
mean + SEM. When two sets of data are labeled with superscripts of different letters, it indicates that these sets of data are statistically different
(P < 0.01) for (A) or (P < 0.05) for (B) and (C).
Roques et al. Veterinary Research 2013, 44:17 Page 6 of 13
http://www.veterinaryresearch.org/content/44/1/17inactivated vaccine group was higher (P < 0.005) than that
of the M-GP5m group at 49 dpi.
The presence of GP5-specific IgG and IgA in BALF
from 8 pigs of each experimental group was determined
by indirect ELISA at 49 dpi (Figure 2B and C). The M-GP5m/rGP5 group developed higher GP5-specific IgG
and IgA responses than the M-GP5 and M-GP5m
groups (P < 0.005), being consistent with the serum re-
sults. However, the Ab response in the M-GP5m/rGP5
group was similar to that observed in pigs of the
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results, pigs of the M-GP5 group showed the lowest
GP5-specific Ab response in BALF.
The presence of NAb was not detected in sera or
BALF of any of the immunized pigs, regardless of the
immunization regime. Finally, it is noteworthy that pigs
immunized with rGP5 did not develop Ab against GST
at any time point of the experiment (data not shown).
Cellular immune response in pigs following immunization
The cell immune responses of six pigs per group that
were used for experimental challenge were evaluated at
28, 35 and 49 dpi. As shown in Figure 3, no significant
differences between the animal groups were observed
due to the high variability in the cellular immune re-
sponse obtained in individual pigs. Nonetheless, the SI
mean in pigs of the M-GP5m group was higher than
that obtained in the other groups at any time point fol-
lowing immunization.
Protective efficiency against PRRSV challenge
Pathological signs and macroscopic lung lesions
One pig in the M-GP5m group suffered from posterior
ataxia and was euthanized at 10 dpc. This animal was
thus not considered in the challenge study. No clinical
signs such as diarrhea, inappetence, cough or dyspnea
were observed in any of the pigs throughout the experi-
mental period of 21 dpc. The body temperature in-
creased slightly at 3 dpc in all pigs but no other change
was observed throughout the 21 dpc period. In addition,
there was no difference in the average daily body weight
gain among all groups of pigs. Percentages of macro-
scopic lung lesions were evaluated at 21 dpc. Pigs of the
inactivated vaccine group showed the lowest macro-
scopic lung lesions (less that 1% in all pigs but one).Figure 3 Lymphocyte proliferative responses in pigs immunized with
quadruplicate were stimulated with inactivated PRRSV (MOI of 200) during
DNA 18 h before cell harvesting. The data are expressed as stimulation ind
the antigen divided by the mean of CPM of cells without antigen. Data rep
group (n = 6 per group) at 28, 35 and 49 days post-immunization are repreThere was no noticeable difference among all other
groups of pigs regardless of the immunization regime
with macroscopic lung lesions less than 5% (data not
shown).
Antibody (Ab) response after experimental challenge
The results of serum GP5-specific Ab response after
challenge are presented in Figure 4A. The GFP, M-GP5
and M-GP5m groups of pigs showed an increase, al-
though not significant, in GP5-specific Abs at 10 dpc.
The M-GP5m/rGP5 animal group had the same level of
GP5-specific Abs before and after challenge whereas in
the inactivated vaccine group there was a significant
diminution of Ab level between 0 and 21 dpc (P < 0.05).
As illustrated in Figure 4B, the level of serum Abs spe-
cific to PRRSV was also determined at 0, 10 and 21 dpc
by the IDEXX ELISA. This ELISA detects Abs mainly
specific to the PRRSV N protein [54,55]. Pigs that had not
received the inactivated vaccine developed N protein-
specific Abs from 10 dpc with no differences in these Ab
levels between groups. As expected, pigs of the inactivated
vaccine group showed a high level of anti-N Abs at 0 dpc.
As shown in Table 1, virus seroneutralization assays
performed with the PRRSV IAF-Klop strain at 21 dpc in-
dicate that all pigs of the inactivated vaccine group de-
veloped NAbs with a titer of 16 in 50% of the pigs. Two
pigs in the M-GP5m/rGP5 group developed NAbs with
titers of 2 and 4, respectively. No pigs from all other ani-
mal groups developed NAb response. When the assays
were conducted with the FMV09-1155278 strain only
pigs of the inactivated group developed NAbs at titers
comparable to those obtained with the IAF-Klop strain
(data not shown).
The presence of GP5-specific IgG and IgA in BALF
was determined at 21 dpc (Figure 5A and B, respectively).recombinant adenoviruses. Peripheral blood mononuclear cells in
72 h. Cells were labeled with radioactive H3-thymidine incorporated
ex (SI) which represents the ratio of mean CPM of cells stimulated with
resent the individual responses of each pig and the means of the
sented by the horizontal bars.
Figure 4 Antibody responses in pig sera challenged with the PRRSV FMV09-1155278 strain. (A) IgG specific to GP5 were detected in
serum samples of pigs at various time points after challenge by indirect ELISA. Data are expressed as mean + SEM. (B) Kinetics of the IgG specific
to PRRSV determined by HerdChek PRRS X3 ELISA are shown. Data are expressed in S/P ratio average. S/P ratio > 0.4 were considered positive
(n = 6 pigs for all groups but the M-GP5m group with 5 pigs).
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Table 1 PRRSV-specific neutralizing antibody titers in
pigs at 21 day post challenge
Group < 2a 2 4 8 16
GFP 6b 0 0 0 0
M-GP5 6 0 0 0 0
M-GP5m 5 0 0 0 0
M-GP5m/rGP5 4 1 1 0 0
Inactivated vaccine 0 0 2 1 3
a Neutralizing antibody titer against the PRRSV IAF-Klop strain.
b Number of pigs.
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http://www.veterinaryresearch.org/content/44/1/17Pigs of the M-GP5m/rGP5 group developed higher (P <
0.0001) GP5-specific IgG response than animals of the
GFP and inactivated vaccine groups. This response was
slightly better but not significantly different from that ob-
served in the M-GP5 and M-GP5m groups of pigs. There
was also no significant difference in the GP5-specific IgG
level between the GFP, M-GP5, M-GP5m and the
inactivated vaccine pig groups. However GP5-specific
IgA level produced in pigs of the M-GP5m/rGP5 group
was significantly higher than that observed in all other
groups of animals (P < 0.05) except the M-GP5 group.
None of the pigs developed NAbs in BALF following
PRRSV challenge.Figure 5 Antibody responses in bronchoalveolar lavage fluids of pigs
was performed to detect IgG (A) and IgA (B) specific to GP5 of pigs at day
for all groups but the M-GP5m group with 5 pigs). When 2 sets of data are
sets of data are statistically different (P < 0.05).Viremia
Viremia was monitored in sera of pigs at 0, 5, 7 and 10 dpc
(Figure 6). The viremia level of the GFP group increased
between 5 and 7 dpc, and was still detectable at 10 dpc
(with a mean of 10.36 in TCID50/mL). The mean level of
viremia of the M-GP5 group was not different when com-
pared to the GFP group at 5 dpc, but decreased from 5
dpc to a mean level of 3.86 TCID50/mL at 10 dpc. The
viremia level in pigs of the M-GP5m group at 5 dpc was
somewhat lower than that of the GFP and M-GP5 groups
and thereafter decreased to nearly undetectable levels at 10
dpc (mean of 0.20 TCID50/mL). Pigs of the inactivated vac-
cine group showed the lowest viremia levels among pigs of
all other groups. The viremia level was almost undetectable
at 7 dpc (mean of 0.21 TCID50/mL) and undetectable at 10
dpc. In contrast, pigs of the M-GP5m/rGP5 group showed
the highest viremia level (mean of 106.42 TCID50/mL) at 5
dpc when compared to that of all other animal groups at 5
dpc (P < 0.05). The viremia level in the M-GP5m/rGP5
group decreased at 7 dpc but still was higher than those of
pigs of the M-GP5m and inactivated vaccine groups (P <
0.05). Viremia in this group was still detectable with a
mean of 1.72 TCID50/mL at 10 dpc.
Discussion
In this study, replicating but nondisseminating human
adenoviruses serotype 5 were used to express PRRSVchallenged with the PRRSV FMV09-1155278 strain. Indirect ELISA
21 post-challenge. Data are expressed as the mean + SEM (n = 6 pigs
labeled with superscripts of different letters, it indicates that these
Figure 6 Viremia of pigs immunized with recombinant adenoviruses and challenged with the PRRSV FMV09-1155278 strain. Pigs were
challenged intranasally with 2 × 105 TCID50 of PRRSV FMV09-1155278 strain at day 49 post primary immunization. The PRRSV loads were
determined at 0, 5, 7 and 10 days post-challenge by quantitative real-time RT-PCR and expressed as TCID50/mL. Data are expressed as the mean
+ SEM (n = 6 pigs for all groups but the M-GP5m group with 5 pigs). When 2 sets of data are labeled with superscripts of different letters at the
same sampling day, it indicates that these sets of data are statistically different (P < 0.05).
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specific immune response. Pigs immunized with rAdV
expressing M-GP5m show higher systemic and mucosal
GP5-specific Ab responses than those of the M-GP5
group using an ELISA. Theoretically, mutations in GP5m
were expected to generate a better NAb response than the
use of WT GP5. The first mutation introduced in GP5m
abolishes the decoy epitope to which a robust non NAb
response has been associated [8]. Moreover, abolishing the
N30 glycosylation site through the same mutation was
also expected to generate a better NAb response [38]. In-
sertion of the PADRE sequence between the decoy and
neutralizing epitopes was also expected to generate better
NAb and T-cell responses as reported elsewhere [23,25].
Finally abrogation of the N51 glycosylation site was also
expected to enhance NAb production [11,56]. Similarly to
pigs of the M-GP5 group, NAbs were not detected in pigs
of the M-GP5m group, nor during the immunization
phase nor following PRRSV experimental challenge. This
result was in contrast with that reported by Li et al. where
immunization of pigs with a plasmid vector expressing a
GP5 protein with similar mutations e.g. insertion of the
PADRE sequence and abrogation of the N30 and N51 gly-
cosylation sites resulted in significant and higher NAb re-
sponse than that observed in animals immunized with anative form of GP5 [22]. Although no NAbs were
detected, a decrease in serum viral load with no complete
elimination of the virus was observed in challenged pigs of
both the M-GP5 and M-GP5m groups at 7 and 10 dpc
when compared to the control GFP group. This decrease
in virus load might be due to higher mean SI in both of
these groups when compared to the mean SI of all other
pig groups before challenge (Figure 3). The virus load de-
crease was even more pronounced in pigs of the M-GP5m
group which showed the highest mean SI at any time
point before challenge. These results might indicate a role
of the cellular immune response in virus clearance as sug-
gested elsewhere [57-59]. However, caution must be made
with this interpretation as pigs of the inactivated vaccine
group showed the lowest viremia levels and SI values in
this study.
Pigs of the M-GP5m/rGP5 group showed the highest
Ab response among all experimental animal groups. This
strong response was observed from one week (e.g. at 28
dpi) following inoculation with rGP5. This was likely
due to the prime-boost regimen used since single inocu-
lation of animals with rGP5 generated an Ab response
only from day 14 after immunization and yet at a much
lower level than that in pigs of the M-GP5m/rGP5group
(data not shown). However, pigs of the M-GP5m
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levels than the control group, indicating that the high
Ab level generated in these pigs did not provide protec-
tion whatsoever but instead appeared to increase viremia.
This increase in viral load can be explained by the
antibody-dependent enhancement (ADE) mechanism by
which non NAb mediate the attachment of PRRSV to
monocyte/macrophage target cells via the Ab Fc receptor
at the surface of these cells, resulting in cell internalization
of the virus, and thereof, increased virus replication [60].
Indeed, the ADE mechanism was suggested to be associ-
ated with PRRSV GP5 decoy epitope and N protein
[61-63]. Further studies are needed to determine whether
the use of rGP5 devoid of a functional decoy epitope
would impact the presumably-ADE associated viremia
level in immunized pigs following experimental challenge
with PRRSV.
Animals of the inactivated vaccine group developed
systemic and mucosal Ab responses. These immune re-
sponses were higher, albeit to non significant levels, than
the M-GP5m during the immunization phase. IgA and
IgG were detected in the lung lavage of animals of the
inactivated vaccine group that were immunized through
the systemic IM route in contrast to animals of the M-
GP5m group that were vaccinated by both the mucosal
(IN) and systemic (IM) routes. The presence of Ab in
the lung lavage of pigs of the inactivated vaccine group
is likely due to the passage of serum Ab through the
lung mucous membranes by passive transudation [64].
Whatever the mechanism is, all pigs of this group devel-
oped significant amounts of serum NAb after challenge
and showed the lowest percentages of gross lesions and
viral load when compared to pigs of all other groups. Al-
though the role of NAb for in vivo protection against
PRRSV is still a debate [65], a minimal serum NAb titer
of 8 comparable to what was obtained in our pigs was
reported to be necessary to prevent viremia [66,67].
In this study, pigs were challenged with a virus strain
heterologous to that used for the immunization phase
due to our difficulty in reproducing clinical disease and
viremia with the IAF-Klop strain. Thus the FMV09-
1155278 PRRSV strain that was recently isolated in
Québec was used for experimental challenge. Moreover
the utilization of a heterologous virus strain for chal-
lenge was of interest as it is well known that PRRSV
antigenic variation occurs under field conditions [68]. It
is noteworthy that the PRRSV FMV09-1155278 strain
has the same GP5 neutralizing epitope sequence
(SHLQLIYNL) as the VR2332 strain-based PRRSV MLV
commercial vaccine used in this study in an inactivated
form. This sequence differs by two aa (in bold and
underlined) when compared to the IAF-Klop neutraliz-
ing epitope (SQLQSIYNL). Thus, NAb titers were
expected to be higher in pigs of the inactivated vaccinegroup using a homologous viral strain in the virus
seroneutralization test. However, the fact that compar-
able NAb titer results were obtained in pigs of the latter
group using either PRRSV IAF-Klop or FMV09-
1155278 strain in the assay might suggest that these aa
are not critical for the GP5 neutralizing epitope. Alter-
nately, the results may reflect different susceptibility of
the virus strains to in vitro neutralization [69].
No clinical signs were observed in the virus-exposed
pigs including control animals indicating that the PRRSV
FMV09-1155278 strain used for challenge was attenu-
ated. This might be attributed to the serial passage of
the virus on MARC145 cells. Despite the absence of
clinical signs, a viremia state, a parameter used in other
studies to ascertain protection in immunized pigs with
or without overt clinical signs following challenge
[15,24,70], was observed in all control animals at 5 dpc.
In addition, pigs of all groups developed an Ab response
specific to the PRRSV N protein at 10 dpc indicating
productive infection in these animals.
In summary replicating but nondisseminating adenovi-
ruses expressing M-GP5 or M-GP5m conferred partial
protection against PRRSV. The degree of immune pro-
tection was better in the case of M-GP5m expression.
Our data were consistent with those of other vector-
based vaccination strategies proposed to date that have
generated only partial protection of animals.
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